The implications of losing treatment options: Why lasmiditan's discontinuation matters
Headache: The Journal of Head and Face Pain · 2026-02 · 66 (2) · 554-555
DOI: 10.1111/head.70041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 05.01.2026. Verfasst von Juliana H VanderPluym. Beteiligte Einrichtung: Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA.
ORCID-Profile: Juliana H VanderPluym
Zitieren
APA
VanderPluym, J. H. (2026). The implications of losing treatment options: Why lasmiditan's discontinuation matters. Headache: The Journal of Head and Face Pain, 66(2), 554-555. https://doi.org/10.1111/head.70041
Vancouver
VanderPluym JH. The implications of losing treatment options: Why lasmiditan's discontinuation matters. Headache: The Journal of Head and Face Pain. 2026;66(2):554-555. doi:10.1111/head.70041
BibTeX
@article{VanderPluym2026,
author = {VanderPluym, Juliana H},
title = {The implications of losing treatment options: Why lasmiditan's discontinuation matters},
journal = {Headache: The Journal of Head and Face Pain},
year = {2026},
volume = {66},
number = {2},
pages = {554--555},
doi = {10.1111/head.70041}
}
EUVIMED